A股異動 | 艾德生物(300685.SZ)漲逾6% 與阿斯利康達成市場推廣合作協議
格隆匯6月23日丨艾德生物(300685.SZ)現報71.17元,漲幅6.22%,最新總市值158億。公司昨日公告稱,近日與阿斯利康簽署了市場推廣協議。公司自主研發的人類BRCA1基因和BRCA2基因突變檢測試劑盒(可逆末端終止測序法)產品及相關診斷方案委託阿斯利康在中國大陸特定區域(即除公司直銷團隊及經銷商服務的客户之外)推廣。公告指,通過整合雙方優勢資源,有助於進一步提高公司綜合競爭力,對公司未來的發展將產生積極影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.